Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
Retrieved on:
Monday, October 3, 2022
Trust, Drawing, Delegation, Stock dilution, EUR, Regulatory News Service, Parity, FDA, BSAP, 13, Phase, Australian dividend imputation system, Program, Extraordinary general meeting, Exercise, Director, Sale, Person, Calendar, Table, Neurodegeneration, 2007 Texas constitutional amendment election, GTO, CET, Degenerative disease, Board of directors, Intellectual property, EMA, Board, Peripheral neuropathy, Therapy, Company, BSA, Security (finance), Credit, Bank, Pharmaceutical industry, Film, Life insurance, Television, Health insurance, Amendment, Bond
As a result of the payment of this first tranche of Bonds and of these repayments, the net amount available to Pharnext will therefore be approximately EUR 2.6 million.
Key Points:
- As a result of the payment of this first tranche of Bonds and of these repayments, the net amount available to Pharnext will therefore be approximately EUR 2.6 million.
- For information purposes, the net amount of the second tranche of Bonds collected by Pharnext, the payment of which is expected later in October 2022, will amount to EUR 2.5 million.
- This results in the maximum nominal amount being reduced to EUR 62 million with respect to this financing program (as opposed to EUR 81 million as initially provided).
- Novacs and Pharnext are currently parties to separate financing agreements with entities that are part of the Alpha Blue Ocean group.